Home/Pipeline/Motpoly XR™

Motpoly XR™

Epilepsy

Not Specified (Likely Phase 3/NDA)Active

Key Facts

Indication

Epilepsy

Phase

Not Specified (Likely Phase 3/NDA)

Status

Active

Company

Aucta Pharmaceuticals

About Aucta Pharmaceuticals

Aucta Pharmaceuticals is a private, US-based specialty pharma company with a dual-site R&D and manufacturing presence in New Jersey and Shanghai. Its strategy centers on using its proprietary AucPed, AucTrol, and AucMist technology platforms to create differentiated dosage forms of established drugs, aiming to improve patient adherence and outcomes. The company is backed by a consortium of global and China-based healthcare investors and is advancing a pipeline focused on CNS and orphan diseases.

View full company profile

Therapeutic Areas

Central Nervous System (CNS) Disorders Metabolic Diseases Orphan and Specialty Indications Ophthalmics Dermatology Pediatrics

Other Epilepsy Drugs

Drug	Company	Phase	Status
Soticlestat (TAK-935)	Takeda Pharmaceutical	Phase 3	Active
UCB4144	UCB	Phase 2	Active
Keppra (levetiracetam)	UCB	Approved	Commercial
NBI-921352	Neurocrine Biosciences	Phase 2	Active
Oxtellar XR®	Supernus Pharmaceuticals	Approved/Commercial	Marketed
ADX71149	Addex Therapeutics	Phase 2	Active (Partner-led)
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active